COMPOSITIONS COMPRISING CANNABINOIDS FOR TREATMENT OF NAUSEA, VOMITING, EMESIS, MOTION SICKNESS OR LIKE CONDITIONS

• US 20120059062A1
• Filed: 08/31/2011
• Published: 03/08/2012
• Est. Priority Date: 02/01/2002
• Status: Abandoned Application

• Current Assignee: GW Pharmaceuticals Limited (Jazz Pharmaceuticals Plc)
• Original Assignee: GW Pharmaceuticals Limited (Jazz Pharmaceuticals Plc)
• Inventors: Whittle, Brian, Javid, Farideh Afshin
• Application Number:
  US13/222,114
• Publication Number:
  US 20120059062A1
• Time in Patent Office: Days
• US Class Current: 514/568
• CPC Class Codes: A61K 2236/10 Preparation or pretreatment of starting material
• CPC Class Codes: A61K 2236/37 Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
• CPC Class Codes: A61K 2236/50 Methods involving additional extraction steps
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 36/185 Magnoliopsida (dicotyledons)
• CPC Class Codes: A61P 1/08 for nausea, cinetosis or vertigo; Antiemetics

Abstract

Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of cannabis plants are presented which are rich in these substances and suitable for pharmaceutical use.

Claims

1-30. -30. (canceled)

31. A pharmaceutical composition comprising cannabidiolic acid (CBDA) or cannabidiolic acid propyl variant (CBDVA).

32. The composition of claim 31, wherein the CBDA or CBDV is in the form of a cannabis based medicinal extract (CBME).

33. The composition of claim 32, wherein the CBME further comprises volatile oils.

34. The composition of claim 33, wherein the volatile oils comprise terpenes or carotenes.

35. The composition of claim 34, wherein the terpenes comprise C10 terpenes, and C15 terpenes.

36. The composition of claim 35, wherein the C10 terpenes comprise myrcenes and pinenes.

37. The composition of claim 35, wherein the C15 terpenes comprise caryophyllene.

38. The composition of claim 32, wherein the CBME is a methanolic or sub-critical carbon dioxide (CO₂) extract.

39. The composition of claim 38, wherein the sub-critical CO₂ extract is obtained under the following conditions:

pressure 60 bar±

10 bar and temperature 10°

C.±

5°

C.

40. The composition of claim 39, wherein the composition has been further purified to remove one or more of:

waxes and other non-specific lipid-soluble material, water, ethanol and colour.

41. The composition of claim 32, wherein the CBME comprises greater than 90% w/w CBDA or CBDVA relative to the other cannabinoids present, measured by HPLC with reference to tetrahydrocannabinol (acid) (THC(A)) and cannabinol (CBN).

42. The composition of claim 41 for use in the treatment of nausea, vomiting, emesis, motion sickness or like conditions.